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Haplotype analysis of APOE intragenic 
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Vladimir N. Babenko1,2*, Dmitry A. Afonnikov1,2, Elena V. Ignatieva1,2, Anton V. Klimov1,2, Fedor E. Gusev3 
and Evgeny I. Rogaev1,3,4,5
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Abstract 
Background: APOE ε4 allele is most common genetic risk factor for Alzheimer’s disease (AD) and cognitive decline. 
However, it remains poorly understood why only some carriers of APOE ε4 develop AD and how ethnic variabilities in 
APOE locus contribute to AD risk. Here, to address the role of APOE haplotypes, we reassessed the diversity of APOE 
locus in major ethnic groups and in Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset on patients with AD, 
and subjects with mild cognitive impairment (MCI), and control non-demented individuals.
Results: We performed APOE gene haplotype analysis for a short block of five SNPs across the gene using the ADNI 
whole genome sequencing dataset. The compilation of ADNI data with 1000 Genomes identified the APOE ε4 linked 
haplotypes, which appeared to be distant for the Asian, African and European populations. The common European 
ε4-bearing haplotype is associated with AD but not with MCI, and the Africans lack this haplotype. Haplotypic infer-
ence revealed alleles that may confer protection against AD. By assessing the DNA methylation profile of the APOE 
haplotypes, we found that the AD-associated haplotype features elevated APOE CpG content, implying that this locus 
can also be regulated by genetic-epigenetic interactions.
Conclusions: We showed that SNP frequency profiles within APOE locus are highly skewed to population-specific 
haplotypes, suggesting that the ancestral background within different sites at APOE gene may shape the disease phe-
notype. We propose that our results can be utilized for more specific risk assessment based on population descent of 
the individuals and on higher specificity of five site haplotypes associated with AD.
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Background
Alzheimer’s disease (AD) is the most frequent case of 
dementia worldwide, which is manifested by a progres-
sive decline in cognitive function due to loss of neurons, 
white matter, and synapses. Although it is thought to 
be caused by progressive accumulation of diffuse and 
neuritic extracellular amyloid plaques and intracellular 
neurofibrillary tangles in the brains of AD patients, the 
etiological mechanisms underlying the neurodegenera-
tion process remain unclear. Since its conception in 2004, 
Alzheimer’s Disease Neuroimaging Initiative (ADNI, 
http://www.adni-info.org/) has been searching for asso-
ciations between MRI brain profiles, biomarkers and 
clinical symptoms. To date, the significant progress has 
been made for neuroimaging of the ADNI subjects and 
in identifying potentially predictive biomarkers for AD 
[1–6]. Importantly, the whole genome sequencing (WGS) 
has also been performed for > 800 subjects in ADNI 
cohort, including AD-patients, individuals with Mild 
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Cognitive Impairment (MCI) and healthy control indi-
viduals (CT) (Materials and methods).
Since 1993, the highly significant association of AD 
with APOE ε4 allele has been demonstrated for vari-
ous ethnic populations [7]. Two missense nucleotide 
polymorphisms (SNPs) of APOE, i.e. rs429358 at codon 
112 and rs7412 at codon 158, determine the genotype 
of APOE for ε2, ε3, and ε4 protein isoforms. In particu-
lar, APOE ε2 represents the major rs429358 variant and 
minor rs7412 variant (TT haplotype, correspondingly), 
while APOE ε3 is presented by (TC) and APOE ε4 by 
(CC) haplotypes. Notably, it was ascertained that sole 
rs429358 is the most common AD-associated variant.
APOE gene encodes a plasma apolipoprotein protein E 
that plays a prominent role in lipid metabolism and cho-
lesterol transport in human tissues [8, 9]. Apolipolipo-
protein E maintains affinity for receptors involved in the 
clearance of remnants of very low density lipoproteins 
[10]. The biological activity of APOE can be altered by 
modification of its structure. The APOE isoforms, E2, E3 
and E4, are metabolically distinct and differ in their affin-
ity for lipoprotein particles and low-density lipoprotein 
receptors [11, 12]. Possession of the APOE ε4 allele, the 
strong genetic factor for AD, facilitates the Aβ deposi-
tion from the presymptomatic stage of AD in a gene-dos-
age-dependent manner. In contrast, the APOE ε2 allele 
appears to decrease AD risk. [13]. Recently, the APOE 
isoforms are shown to differentially modulate the cellu-
lar uptake of Aβ mediated by sortilin related receptor 1 
(LR11/SorLA) [14]. Thus, it is also plausible that APOE 
isoforms differentially induce the AD pathology through 
their cooperation with LR11/SorLA, which is involved 
in the lysosomal targeting of extracellular amyloid-β 
(Aβ) [15]. However, the exact molecular mechanism 
underlying the genetic association of AD with APOE 
[16] remains poorly understood. The presumable DNA 
methylation shifts for APOE alleles in aging may poten-
tially contribute to differential regulation of APOE alleles 
[17, 18]. Interestingly, the pattern of AD-association with 
APOE varies across human populations. For example, 
APOE ε4 association with AD is lower or even lacking in 
African-Americans, Hispanic or Yoruban-African popu-
lations [19–21]. At the same time, the risk of developing 
AD in APOE ε4 carriers can be modified by other genetic 
variants, for example, allele G of rs2373115 in gene GAB2 
was reported to increase the risk [22].
In this study, we investigated the population dynamics 
of APOE haplotypes and their association with AD devel-
opment. We also assessed APOE methylation profile and 
found that some intragenic SNPs can be connected to 
APOE DNA methylation shift.
Datasets and methods
ADNI data
Data used in the preparation of this article were obtained 
from the Alzheimer’s Disease Neuroimaging Initiative 
(ADNI) database (adni.loni.usc.edu). The ADNI was 
launched in 2003 as a public–private partnership, led by 
Principal Investigator Michael W. Weiner, MD. The pri-
mary goal of ADNI was to test whether serial magnetic 
resonance imaging (MRI), positron emission tomography 
(PET), other biological markers, and clinical and neu-
ropsychological assessment can be combined to measure 
the progression of mild cognitive impairment (MCI) and 
early Alzheimer’s disease (AD). For up-to-date informa-
tion, see www.adni-info.org.
Whole genome sequencing data for 809 subjects in 
VCF format have been downloaded from ADNI web 
site. It comprised 183 AD-affected individuals, 370 Mild 
Cognitive Impairment (MCI) ones and 256 of healthy 
individuals (CT) (http://adni.loni.usc.edu/wp-content/
uploads/2010/09/ADNI_WGS_Notice_20130917.pdf ). 
The dataset consists mainly of White individuals (94%). 
The variant data were called using Illumina’s CASAVA 
SNP Caller (http://support.illumina.com/sequencing/
sequencing_software/casava.html) and are available in 
VCF format.
1000 Genomes data
We prepared a subset of 1000 Genomes data for 3 
populations: (a) African (97 individuals from Luhya 
in Webuye, Kenya (LWK); 88 individuals of Yoruba in 
Ibadan, Nigeria (YRI); 185 individuals total), (b) East 
Asian (Han Chinese Southern (CHS0—100 individuals, 
Han Chinese in Bejing (CSB)—97 individuals, Japanese 
in Tokyo (JPT)—89 individuals; 286 total); (c) European 
sample (88 individuals from British in England and Scot-
land (GBR); 98 individuals from Toscani in Italia (TSI); 94 
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individuals from Finnish in Finland (FIN); 85 individuals 
from Utah Residents (CEPH) with Northern and West-
ern European Ancestry; 365 total). The data is available at 
http://www.internationalgenome.org/data/.
Association analysis
For association analysis in APOE locus we excluded all 
genetic variants with allele frequency (MAF) less than 
1%, call rates less than 98% or not in Hardy–Weinberg 
equilibrium (P < 10−4 in controls). Then we used R-based 
GenABEL program [23] for assessing the association with 
AD, using a AD individuals as cases and excluding MCI 
individuals from analysis. Using the threshold of 5E−8 
to select the statistically significant associations with AD 
phenotype resulted in 27 SNPs from chromosome 19 in 
APOE vicinity (Additional file  1: Table S1; Additional 
file 2: Fig. S1). Two of these 27 SNPs were located within 
APOE gene (Table 1).
Haplotype analysis
We used Arlequin ver 3.5 [24], Haploview (https://www.
broadinstitute.org/haploview/downloads), PLINK [25] 
software for assessing linkage disequilibrium and hap-
lotype inferences in APOE locus region. In particular, 
we used ‘haploblocks’ option of Haploview to segregate 
SNPs into blocks based on ‘tagged’ SNPs [26] algorithm. 
A block is defined as consequent SNP set over which 95% 
of informative pairwise comparisons are in strong LD 
[26].
We inferred the most likely gametic phases of 5 locus 
genotypes using a pseudo-Bayesian approach (ELB algo-
rithm) [24]. Based on the phased haplotype profiles we 
inferred the ML haplotype phylogenetic tree for 5 SNPs 
within the APOE locus. Due to strong linkage disequilib-
rium at the region [16], the in silico phasing has proved 
to be non-ambiguous and thus efficient in this particular 
case. The pairwise comparison of haplotype frequencies 
has been carried out by Conventional F-test implemented 
in Arlequin software [24]. In particular, Average num-
ber of pairwise differences between populations P(X,Y) 
has been calculated, then average pairwise differences 
within populations has been carried out denoted by P(X). 
Lastly, the corrected pairwise differences between popu-
lations was calculated as P’(X,Y) = (P(X,y) − (P(X) + P(Y)
)/2) [24]. P values have been calculated by Monte-Carlo 
Method based on 100,000 simulations for each pair.
We used XLStat software for Principal Components 
analysis (www.xlstat.com).
Haplotype-specific association analysis was performed 
with Fisher’s exact test against the most common Euro-
pean haplotype (GGATC).
Phylogenetic analysis
PHYLIP DNAML software was used to build an unrooted 
phylogenetic tree of observed haplotype sequences.
Methylation profile analysis
For methylation analysis of APOE, we used ENCODE 
epigenetic profiles for 63 cell lines obtained using Illu-
mina Infinium Human Methylation 450 platform (http://
www.genome.ucsc.edu/cgi-bin/hgTrackUi?hgsid=61243
8305_2wY2cahV1lPNoxcvDm5zHm99hpjz&c=chr19&g
=wgEncodeHaibMethyl450) and DNA methylation pro-
files of human fetal brain [27].
Results
Analysis of SNP frequencies in APOE gene revealed 
that only five of them are common in human popula-
tion with frequency > 5% (Fig. 1, Table 2). Three of these 
SNPs are non-coding variants. The other two (rs429358 
and rs7412) are missense variations that define APOE ε2, 
ε3 and ε4 isoforms. We focused on haplotype analysis of 
these five genetic variants.  
In line with previous reports, we found multiple SNPs 
in APOE locus to have a significant association to AD 
(Additional file  1: Table S1; Additional file  2: Fig S1). 
However, only two of the above five SNPs in APOE gene 
(rs769449 and rs429358) show statistically significant 
association with AD (Table 1).
Next, we conducted a haplotype-based analysis of 
the five SNPs. Pairwise linkage analysis revealed that 
rs769449 and rs429358 are linked in Asian individuals 
(r2 = 0.956), but have a lower linkage in European sam-
ple (r2 = 0.828), while rs769449 is not polymorphic in 
Africans. Further, using Arlequin software, we assessed 
haplotype frequencies (haplotypes with f > 0.01) for six 
human cohorts (Fig. 2, Table 3).
Analysis of these data demonstrated that haplotype fre-
quency profiles are distinct in human populations (Fig. 3, 
Table  3). This is supported by statistical analysis, which 
demonstrated that each pair of populations/cohorts are 
significantly different (P value < 1e−4), except, for 1000 
Genomes European population versus ADNI Control 
cohort (Table  4). The most common haplotypes (which 
are presented by APOE ε3-bearing alleles) have different 
Table 1 Two highly significant SNPs within APOE gene 
locus revealed by ADNI GWA analysis
P value genotypes P value alleles
rs769449 8,6E − 15 4,3E − 14
rs429358 4,8E − 18 2,58E − 17
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frequencies across populations: GGGTC is almost absent 
in Europeans (< 1%) and Asians (< 2%), but common 
in Africans (20%), CGGTC is present in 62% of Asians, 
but at lower frequencies in Europeans (36%) and Afri-
cans (13%). We also observed that two most common 
ε4—bearing haplotypes have a clear population-specific 
patterns. GAGCC is present exclusively in Asian and 
European populations and absent in African population. 
In contrast GGGCC is the only ε4—bearing haplotype 
presented in 29% of African individuals, but occurs at low 
frequencies in Asian and European groups (< 2%). Sur-
prisingly, a protective APOE ε2 allele is presented almost 
Fig. 1 Minor allele frequencies of five SNPs included in analysis. Intronic rs769449 and APOE ε4 rs429358 SNPs with significant association to AD are 
encircled
Table 2 Minor allele frequencies of 5 SNPs included in analysis. SNPs are sorted by chromosomal position. SNPs with sig-
nificant association to AD in bold
SNP ID Alleles (MAF  1st) Type Global MAF 1000G (MAF) samples ADNI (MAF) samples
Afr Asian Eur AD MCI CT
rs440446 C/G Noncoding 0.37 0.130 0.371 0.367 0.279 0.355 0.383
rs769449 A/G Noncoding 0.06 0.000 0.084 0.121 0.314 0.168 0.098
rs769450 A/G Noncoding 0.33 0.289 0.192 0.423 0.276 0.347 0.389
rs429358 C/T Missense 0.15 0.292 0.087 0.141 0.418 0.218 0.139
rs7412 T/C Missense 0.07 0.084 0.075 0.067 0.022 0.058 0.070
Sample size 185 286 365 183 370 256
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exclusively by a single haplotype GGGTT in all human 
populations with 6–8% frequency. Thus, this allele has a 
lower population diversity. 
Phylogenetic analysis of APOE haplotypes revealed that 
APOE ε4 haplotype GGGCC, which is African-specific, 
is most likely the ancestral variant (Fig. 4). This suggests 
that a common APOE ε3 allele was distributed in human 
populations after the split with other archaic hominins.
Comparing nucleotide content in the two ε4-bearing 
haplotypes (GGGCC and GAGCC) we observed that 
allele G of second SNP (rs769449) separates Africans 
from individuals of European and Asian ancestry. When 
we compared these two haplotypes to the most com-
mon European haplotype (GGATC), we found that both 
are significantly associated with AD (Fisher’s exact test 
P value < 1e−12 and P value < 1e−4), but only GAGCC 
is associated with MCI. Altogether the data suggests, 
the state of this SNP might have a modifying effect on 
ε4-associated AD/MCI risk development with African-
specific allele G being potentially protective, in particular, 
in African populations.
This SNP is non-coding and therefore might have a 
regulatory effect on APOE. Potentially, A vs G allele in 
rs769449 can modify the epigenetic state in the APOE 
gene region. Supporting this hypothesis, we observed 
a robust H3K4Me3 signal using ChIP-seq data in this 
rs769449-containing region (Fig.  5; encircled) that is 
common mark of open chromatin. We assessed meth-
ylation profile of APOE locus based on ENCODE HAIB 
methylation data performed using Illumina Human 
Methylation 450  K Bead Arrays (Fig.  5) [18, 27]. While 
the methylation profile is U-shaped, the region from 
TSS down to exon 4 is highly sensitive to methylation 
[18], and comprises a range of transcription factor bind-
ing sites (Additional file  1: Table S2). The methylation 
rate of this region, which includes the SNP rs769449, is 
Fig. 2 Haplotype frequencies in human populations and ADNI cohort. X-axis labels represent allelic status of 5 SNPs (rs440446, rs769449, rs769450, 
rs429358,rs7412; Table 2) in APOE locus. Haplotype associated with APOE ε4 are in bold italic
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anticorrelated with APOE expression rate and is signifi-
cantly associated with aging [18]. It is also located 78 bp 
downsteam to second APOE exon. The methylation state 
in this region is changed in aging and associated with 
APOE dysfunction [18]. The rs769449 context is (gGc) 
and, when turning to A, one of the methylation sites 
drops out, thus possibly altering intragenic methylation 
profile. A set of transcription factor binding sites in the 
areas of SNPs rs769449 also implies its possible regula-
tory effect (Additional file 1: Table S2).
 It is worth noting that at least three out of five SNPs 
affect the CG dinucleotide content in APOE gene. APOE 
ε4 bears two CG dinucleotides mediated by rs429358 
(minor allele) and rs7412 (major allele) that reside in 
the CpG island of exon 4 (Fig. 5) [18, 28]. rs769450 does 
not affect CG content (Table 2), while rs440446, the first 
target haplotype SNP meditates the CG dinucleotide 
arisen by minor allele, similar to the last ones,. Thus, the 
APOE ε4-bearing haplotypes maintain the largest num-
ber of CG dinucleotides within APOE (Table 3). Notably, 
rs769449 mediates CG dinucleotide in the inverse strand. 
It is resided within hotspot of H3K3me3 region (Fig.  6; 
encircled), and its C→A transition might affect the bind-
ing site of the transcription factor (Additional file 1: Table 
Fig. 3 Principal Components analysis based on the haplotype frequencies distribution across 6 populations (Afr, Ori, Eur, AD, MCI, CT). Haplotype 
encoding corresponds to Table 2. AD—associated haplotypes are marked by the bold italic type
Table 4 P value for pairwise comparison of populations 
based on their haplotype frequencies [24]. ADNI Control 
group and European population don’t significantly differ
Afr Ori Eur AD MCI
Ori < 10E − 4
Eur < 10E − 4 < 10E − 4
AD < 10E − 4 < 10E − 4 < 10E − 4
MCI < 10E − 4 < 10E − 4 < 10E − 4 < 10E − 4
CT < 10E − 4 < 10E − 4 0.5 < 10E − 4 0.00909
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S1). Notably, the target Illumina Methylation 450 array 
CpG site cg06750524 located close to rs769449 (Fig.  6; 
encircled) methylation status is highly associated with 
APOE ε4 allele: it was reported that its methylation rate 
is higher for the minor “disease” allele [18].
Discussion
APOE gene maintains the highest genetic association 
with AD reported to date. However, the association is 
ethnic- dependent, e.g., the evidence for AD-association 
with APOE is lower for African-Americans, Hispanic or 
Yoruban-African populatuion [19–21]. We have demon-
strated that frequencies of APOE haplotypes a signifi-
cantly different in human populations (Fig.  2, Table  4). 
Specifically, the context of APOE ε4, which is the AD risk 
allele, drastically differs in populations (Fig. 3, Table 3). In 
particular, the two haplotypes for AD-associated APOE 
ε4 variant are GGGCC for African, and CAGCC for 
European and Asian individuals.
Sequence analysis of the chimpanzee APOE gene 
showed that it is most closely related to human ε4-type 
haplotypes, differing from the human consensus 
sequence at 67 synonymous (54 substitutions and 13 
indels) and 9 nonsynonymous fixed positions [29]. Our 
analysis showed further that haplotypes defining the ε3 
and ε2 alleles are derived from the ancestral ε4 s and that 
the ε3 group of haplotypes have increased in European 
and Asian populations.
Fig. 4 Phylogenetic tree of APOE haplotypes. GAGCC is the disease haplotype specific to Europeans (Table 3). The AD-associated haplotype subset 
is encircled
Page 37 of 40Babenko et al. BMC Neurosci 2018, 19(Suppl 1):16
 The issue of ancestry of APOE ε4 allelotype has been 
widely discussed [30], and it has been established that the 
C→ T variant for ε3 allele arose after primate radiation 
[30]. Its relatively rapid expansion could be attributed to 
converging to meat diet in ancient human populations 
[30]. The data suggest also that specific APOE haplotypes 
might have protective effect against AD development 
potentially via epigenetic reprogramming of APOE due 
to CpG emergence/dropout [18, 28]. Altogether, our data 
demonstrated that ethnic genetic background defines 
Fig. 5 Methylation profile of the APOE locus. a Genomic location of Illumina Methyl 450 bead array probes; b methylation profile of APOE gene 
based on two methylome projects. 63 HAIB cell lines (HAIB ENCODE methylation data), and 179 fetal brain samples [27] were used. Vertical dotted 
bars correspond to standard deviation of methylation score. Arrows indicate age related methylation drive [18]
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significant differences in haplotypes for AD- risk alleles 
in human populations that may potentially be additional 
factor modifying risk for AD.
Abbreviations
AD: Alzheimer’s disease; LOD: Logarithm of odds; SNPs: Single nucleotide 
polymorphisms.
About this supplement
This article has been published as part of BMC Neuroscience Volume 19 Sup-
plement 1, 2018: Selected articles from Belyaev Conference 2017: neurosci-
ence. The full contents of the supplement are available online at https://bmc-
neurosci.biomedcentral.com/articles/supplements/volume-19-supplement-1.
Authors’ contributions
E IR, DAA and VNB participated in project conception and in the study design. 
EIR and FEG coordinated downloading of genotype data from the ADNI web 
site. VNB and FEG assessed linkage disequilibrium and haplotype inferences 
in APOE locus region; VNB performed PCA analysis and analyzed methylation 
profiles. DAA and AVK performed statistical analysis with GenABEL program. 
EVI contributed to data interpretation. All authors read and approved the final 
manuscript.
Additional files
Additional file 1: Table S1. 27 significant SNPs in the APOE region. 
Table S2. Transcription factor binding sites annotation related to SNPs 
analysed.
Additional file 2: Fig. S1. Output of GenABEL [23] program underlining 
chromosome 19 APOE region significance on ADNI sample.
Author details
1 The Federal Research Center Institute of Cytology and Genetics of Siberian 
Branch of the Russian Academy of Sciences, Center of Neurobiology and Neu-
rogenetics, Lavrentieva str. 10, Novosibirsk, Russia 630090. 2 Novosibirsk 
State University, Pirogova Str, 2, Novosibirsk, Russia 630090. 3 Vavilov Institute 
of General Genetics RAS, Gubkina str. 3, Moscow, Russia 119991. 4 Department 
of Psychiatry, University of Massachusetts Medical School, BNRI, Worcester, MA 
15604, USA. 5 Faculty of Biology, Faculty of Bioengineering and Bioinformatics, 
Lomonosov Moscow State University, Moscow, Russia 119234. 
Acknowledgements
The authors are grateful to anonymous reviewers for their valuable comments 
on our manuscript. Data collection and sharing for this project was funded by 
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of 
Health Grant U01 AG024904) and DOD ADNI (Department of Defense Award 
Number W81XWH-12-2-0012). ADNI is funded by the National Institute on 
Aging, the National Institute of Biomedical Imaging and Bioengineering, and 
through generous contributions from the following: AbbVie, Alzheimer’s Asso-
ciation; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, 
Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; 
Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La 
Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; 
IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; 
Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; 
Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; 
Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; 
Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition 
Therapeutics. The Canadian Institutes of Health Research is providing funds 
to support ADNI clinical sites in Canada. Private sector contributions are 
facilitated by the Foundation for the National Institutes of Health (www.fnih.
org). The grantee organization is the Northern California Institute for Research 
and Education, and the study is coordinated by the Alzheimer’s Therapeutic 
Research Institute at the University of Southern California. ADNI data are dis-
seminated by the Laboratory for Neuro Imaging at the University of Southern 
California.
Fig. 6 UCSC genome browser screenshot depicting active H3K4me3 spot in the vicinity of rs769449 (encircled) along with previously associated 
with APOE ε4 cg06750524 methylation status [18]
Page 39 of 40Babenko et al. BMC Neurosci 2018, 19(Suppl 1):16
Evgeny I. Rogaev: For the Alzheimer’s Disease Neuroimaging Initiative 
(ADNI): ADNI data used in preparation of this article were obtained from the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.
edu). As such, the investigators within the ADNI contributed to the design 
and implementation of ADNI and/or provided data but did not participate in 
analysis or writing of this report. A complete listing of ADNI investigators can 
be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/
ADNI_Acknowledgement_List.pdf.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
The ADNI dataset analyzed in this study is available from ADNI consortium 
upon request.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Funding
The present study was supported in part by the Government of the Russian 
Federation, Grant No. 14.B25.31.0033, Resolution No. 220 (assessing linkage 
disequilibrium and haplotype inferences in APOE locus region, haplotype and 
PCA analysis), in part, E.I.R. supported by R01AG54712-02 and ADDF. Dmitry 
A. Afonnikov and Anton V, Klimov acknowledge the support of the statistical 
analysis with GenABEL program by the Federal Agency of Scientific Organiza-
tions, Project 0324-2018-0017. This work was also supported in part by Russian 
Science Foundation #14-44-00077 (ADNI data analysis) and #14-50-00029 
(population analysis). The publication costs for this article were funded by the 
project 0324-2018-0017.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Published: 19 April 2018
References
 1. Takei N, Miyashita A, Tsukie T, Arai H, Asada T, Imagawa M, Shoji M, 
Higuchi S, Urakami K, Kimura H, Kakita A, Takahashi H, Tsuji S, Kanazawa 
I, Ihara Y, Odani S, Kuwano R. Japanese genetic study consortium for 
Alzheimer Disease. Genetic association study on in and around the APOE 
in late-onset Alzheimer disease in Japanese. Genomics. 2009;93(5):441–8. 
https://doi.org/10.1016/j.ygeno.2009.01.003.
 2. Liu M, Bian C, Zhang J, Wen F. Apolipoprotein E gene polymorphism 
and Alzheimer’s disease in Chinese population: a meta-analysis. Sci Rep. 
2014;4:4383. https://doi.org/10.1038/srep04383.
 3. Lutz MW, Sundseth SS, Burns DK, Saunders AM, Hayden KM, Burke JR, 
Welsh-Bohmer KA, Roses AD. A Genetics-based biomarker risk algorithm 
for predicting risk of Alzheimer’s Disease. Alzheimers Dement (N Y). 
2016;2(1):30–44.
 4. Anderson ED, Wahoske M, Huber M, Norton D, Li Z, Koscik RL, Umucu 
E, Johnson SC, Jones J, Asthana S, Gleason CE. Alzheimer’s disease 
neuroimaging initiative. Cognitive variability-a marker for incident MCI 
and AD: an analysis for the Alzheimer’s Disease neuroimaging initiative. 
Alzheimers Dement (Amst). 2016;4:47–55. https://doi.org/10.1016/j.
dadm.2016.05.003.
 5. Luo X, Qiu T, Jia Y, Huang P, Xu X, Yu X, Shen Z, Jiaerken Y, Guan X, Zhou J, 
Zhang M. ADNI. Intrinsic functional connectivity alterations in cognitively 
intact elderly APOE ε4 carriers measured by eigenvector centrality map-
ping are related to cognition and CSF biomarkers: a preliminary study. 
Brain Imaging Behav. 2017;11(5):1290–301. https://doi.org/10.1007/
s11682-016-9600-z.
 6. Shen L, Kim S, Risacher SL, Nho K, Swaminathan S, West JD, Foroud T, 
Pankratz N, Moore JH, Sloan CD, Huentelman MJ, Craig DW, Dechairo BM, 
Potkin SG, Jack CR Jr, Weiner MW, Saykin AJ. Alzheimer’s Disease neuroim-
aging initiative. Whole genome association study of brain-wide imaging 
phenotypes for identifying quantitative trait loci in MCI and AD: a study 
of the ADNI cohort. Neuroimage. 2010;53(3):1051–63.
 7. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small 
GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein 
E type 4 allele and the risk of Alzheimer’s disease in late onset families. 
Science. 1993;261(5123):921–3.
 8. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and 
atherosclerosis. Arteriosclerosis. 1988;8(1):1–21.
 9. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure 
determines function, from atherosclerosis to Alzheimer’s disease to 
AIDS. J Lipid Res. 2009;50(Suppl):S183–8. https://doi.org/10.1194/jlr.
R800069-JLR200.
 10. Blum CB, Type III. Hyperlipoproteinemia: still Worth Considering? 
Prog Cardiovasc Dis. 2016;59(2):119–24. https://doi.org/10.1016/j.
pcad.2016.07.007.
 11. Hui DY, Innerarity TL, Mahley RW. Defective hepatic lipoprotein receptor 
binding of beta-very low density lipoproteins from type III hyperlipo-
proteinemic patients. Importance of apolipoprotein E. J Biol Chem. 
1984;259(2):860–9.
 12. Mooijaart SP, Berbée JF, van Heemst D, Havekes LM, de Craen AJ, Slag-
boom PE, Rensen PC, Westendorp RG. APOE plasma levels and risk of 
cardiovascular mortality in old age. PLoS Med. 2006;3(6):e176.
 13. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, 
Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales 
KR, Paul SM, Bateman RJ, Holtzman DM. Human APOE isoforms dif-
ferentially regulate brain amyloid-β peptide clearance. Sci Transl Med. 
2011;3(89):89ra57. https://doi.org/10.1126/scitranslmed.3002156.
 14. Yajima R, Tokutake T, Koyama A, Kasuga K, Tezuka T, Nishizawa M, Ikeuchi 
T. APOE-isoform-dependent cellular uptake of amyloid-β is mediated 
by lipoprotein receptor LR11/SorLA. Biochem Biophys Res Commun. 
2015;456(1):482–8. https://doi.org/10.1016/j.bbrc.2014.11.111.
 15. Caglayan S, Takagi-Niidome S, Liao F, Carlo AS, Schmidt V, Burgert 
T, Kitago Y, Füchtbauer EM, Füchtbauer A, Holtzman DM, Takagi J, 
Willnow TE. Lysosomal sorting of amyloid-β by the SORLA receptor is 
impaired by a familial Alzheimer’s disease mutation. Sci Transl Med. 
2014;6(223):223ra20. https://doi.org/10.1126/scitranslmed.3007747.
 16. Jun G, Vardarajan BN, Buros J, Yu CE, Hawk MV, Dombroski BA, Crane PK, 
Larson EB; Alzheimer’s Disease Genetics Consortium., Mayeux R, Haines 
JL, Lunetta KL, Pericak-Vance MA, Schellenberg GD, Farrer LA. Compre-
hensive search for Alzheimer disease susceptibility loci in the APOE 
region. Arch Neurol. 2012;69(10):1270-1279. https://doi.org/10.1001/
archneurol.2012.2052.
 17. Wang SC, Oelze B, Schumacher A. Age-specific epigenetic drift in 
late-onset Alzheimer’s disease. PLoS ONE. 2008;3(7):e2698. https://doi.
org/10.1371/journal.pone.0002698.
 18. Ma Y, Smith CE, Lai CQ, Irvin MR, Parnell LD, Lee YC, Pham L, Aslibekyan 
S, Claas SA, Tsai MY, Borecki IB, Kabagambe EK, Berciano S, Ordovás JM, 
Absher DM, Arnett DK. Genetic variants modify the effect of age on APOE 
methylation in the genetics of lipid lowering drugs and diet network 
study. Aging Cell. 2015;14(1):49–59. https://doi.org/10.1111/acel.12293.
 19. Barnes LL, Bennett DA. Alzheimer’s disease In African Americans: 
risk factors and challenges for the future. Health Aff (Project Hope). 
2014;33(4):580–6. https://doi.org/10.1377/hlthaff.2013.1353.
 20. Hendrie HC, Murrell J, Baiyewu O, Lane KA, Purnell C, Ogunniyi A, Gao S. 
APOE ε4 and the risk for Alzheimer disease and cognitive decline in Afri-
can Americans and Yoruba. Int Psychogeriatr. 2014;26(6):977–85. https://
doi.org/10.1017/S1041610214000167.
 21. Tang MX, Stern Y, Marder K, Bell K, Gurland B, Lantigua R, Mayeux R. The 
APOE-epsilon4 allele and the risk of Alzheimer disease among African 
Americans, whites, and Hispanics. JAMA. 1998;279(10):751–5.
 22. Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zismann VL, 
Joshipura KD, Pearson JV, Hu-Lince D, Huentelman MJ, Craig DW, Coon 
KD, Liang WS, Herbert RH, Beach T, Rohrer KC, Zhao AS, Leung D, Bryden 
L, Marlowe L, Kaleem M, Mastroeni D, Grover A, Heward CB, Ravid R, Rog-
ers J, Hutton ML, Melquist S, Petersen RC, Alexander GE, Caselli RJ, Kukull 
W, Papassotiropoulos A, Stephan DA. GAB2 alleles modify Alzheimer’s risk 
in APOE epsilon4 carriers. Neuron. 2007;54(5):713–20.
Page 40 of 40Babenko et al. BMC Neurosci 2018, 19(Suppl 1):16
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 23. Aulchenko YS, Ripke S, Isaacs A, van Duijn CM. GenABEL: an R library for 
genome-wide association analysis. Bioinformatics. 2007;23(10):1294–6.
 24. Excoffier L, Lischer HE. Arlequin suite ver 3.5: a new series of pro-
grams to perform population genetics analyses under Linux 
and Windows. Mol Ecol Resour. 2010;10(3):564–7. https://doi.
org/10.1111/j.1755-0998.2010.02847.x.
 25. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller 
J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-
genome association and population-based linkage analyses. Am J Hum 
Genet. 2007;81(3):559–75.
 26. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Hig-
gins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adey-
emo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D. The structure of 
haplotype blocks in the human genome. Science. 2002;296:2225–9.
 27. Spiers H, Hannon E, Schalkwyk LC, Smith R, Wong CC, O’Donovan 
MC, Bray NJ, Mill J. Methylomic trajectories across human fetal brain 
development. Genome Res. 2015;25(3):338–52. https://doi.org/10.1101/
gr.180273.114.
 28. Yu CE, Foraker J. Epigenetic considerations of the APOE gene. Biomol 
Concepts. 2015;6(1):77–84. https://doi.org/10.1515/bmc-2014-0039.
 29. Fullerton SM, Clark AG, Weiss KM, Nickerson DA, Taylor SL, Stengârd JH, 
Salomaa V, Vartiainen E, Perola M, Boerwinkle E, Sing CF. Apolipoprotein 
E variation at the sequence haplotype level: implications for the origin 
and maintenance of a major human polymorphism. Am J Hum Genet. 
2000;67(4):881–900.
 30. Finch CE. Evolution in health and medicine Sackler colloquium: evolution 
of the human lifespan and diseases of aging: roles of infection, inflamma-
tion, and nutrition. Proc Natl Acad Sci U S A. 2010;107(Suppl 1):1718–24. 
https://doi.org/10.1073/pnas.0909606106.
